#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4. Discussion
1-1	0-2	4.	_	_	_	_
1-2	3-13	Discussion	abstract	new	_	_

#Text=Diet
2-1	14-18	Diet	organization	new	_	_

#Text=interventions are well-established strategies to reduce body weight and improve glucose metabolism , however no evidence exists about the effects of periodic fasting on NAFLD .
3-1	19-32	interventions	abstract	new	coref	3-3[4_0]
3-2	33-36	are	_	_	_	_
3-3	37-53	well-established	abstract[4]	giv[4]	coref	11-8[70_4]
3-4	54-64	strategies	abstract[4]	giv[4]	_	_
3-5	65-67	to	abstract[4]	giv[4]	_	_
3-6	68-74	reduce	abstract[4]	giv[4]	_	_
3-7	75-79	body	abstract[4]|object|abstract[6]	giv[4]|new|new[6]	coref|coref	12-16[0_6]|20-3[118_0]
3-8	80-86	weight	abstract[4]|abstract[6]	giv[4]|new[6]	_	_
3-9	87-90	and	abstract[4]	giv[4]	_	_
3-10	91-98	improve	abstract[4]|event|abstract	giv[4]|new|new	none|none|none	3-10|8-11|3-10[0_268]
3-11	99-106	glucose	abstract[4]|substance|abstract[8]	giv[4]|new|new[8]	_	_
3-12	107-117	metabolism	abstract[4]|abstract[8]	giv[4]|new[8]	_	_
3-13	118-119	,	_	_	_	_
3-14	120-127	however	_	_	_	_
3-15	128-130	no	abstract[9]	new[9]	coref	20-7[119_9]
3-16	131-139	evidence	abstract[9]	new[9]	_	_
3-17	140-146	exists	_	_	_	_
3-18	147-152	about	_	_	_	_
3-19	153-156	the	abstract[10]	new[10]	_	_
3-20	157-164	effects	abstract[10]	new[10]	_	_
3-21	165-167	of	abstract[10]	new[10]	_	_
3-22	168-176	periodic	abstract[10]|event[11]	new[10]|new[11]	coref	4-12[15_11]
3-23	177-184	fasting	abstract[10]|event[11]	new[10]|new[11]	_	_
3-24	185-187	on	abstract[10]|event[11]	new[10]|new[11]	_	_
3-25	188-193	NAFLD	abstract[10]|event[11]|abstract	new[10]|new[11]|new	coref	10-5
3-26	194-195	.	_	_	_	_

#Text=This study is the first to show the beneficial effects of periodic fasting on fatty liver .
4-1	196-200	This	abstract[13]	new[13]	coref	5-4[19_13]
4-2	201-206	study	abstract[13]	new[13]	_	_
4-3	207-209	is	_	_	_	_
4-4	210-213	the	_	_	_	_
4-5	214-219	first	_	_	_	_
4-6	220-222	to	_	_	_	_
4-7	223-227	show	_	_	_	_
4-8	228-231	the	abstract[14]	new[14]	_	_
4-9	232-242	beneficial	abstract[14]	new[14]	_	_
4-10	243-250	effects	abstract[14]	new[14]	_	_
4-11	251-253	of	abstract[14]	new[14]	_	_
4-12	254-262	periodic	abstract[14]|event[15]	new[14]|giv[15]	coref	5-29[0_15]
4-13	263-270	fasting	abstract[14]|event[15]	new[14]|giv[15]	_	_
4-14	271-273	on	abstract[14]|event[15]	new[14]|giv[15]	_	_
4-15	274-279	fatty	abstract[14]|event[15]|object[16]	new[14]|giv[15]|new[16]	coref	5-16[23_16]
4-16	280-285	liver	abstract[14]|event[15]|object[16]	new[14]|giv[15]|new[16]	_	_
4-17	286-287	.	_	_	_	_

#Text=The results of our study supported the hypothesis that FLI , a surrogate parameter of fatty liver , significantly decreases in individuals with and without T2DM after a fasting intervention of at least 6 days .
5-1	288-291	The	abstract[17]	new[17]	coref	8-1[42_17]
5-2	292-299	results	abstract[17]	new[17]	_	_
5-3	300-302	of	abstract[17]	new[17]	_	_
5-4	303-306	our	abstract[17]|person|abstract[19]	new[17]|acc|giv[19]	coref|ana	6-3[0_19]|8-1
5-5	307-312	study	abstract[17]|abstract[19]	new[17]|giv[19]	_	_
5-6	313-322	supported	_	_	_	_
5-7	323-326	the	abstract[20]	new[20]	coref	19-4[113_20]
5-8	327-337	hypothesis	abstract[20]	new[20]	_	_
5-9	338-342	that	abstract[20]	new[20]	_	_
5-10	343-346	FLI	abstract[20]|abstract	new[20]|new	appos	5-12[22_0]
5-11	347-348	,	abstract[20]	new[20]	_	_
5-12	349-350	a	abstract[20]|abstract[22]	new[20]|giv[22]	coref	9-15[0_22]
5-13	351-360	surrogate	abstract[20]|abstract[22]	new[20]|giv[22]	_	_
5-14	361-370	parameter	abstract[20]|abstract[22]	new[20]|giv[22]	_	_
5-15	371-373	of	abstract[20]|abstract[22]	new[20]|giv[22]	_	_
5-16	374-379	fatty	abstract[20]|abstract[22]|object[23]	new[20]|giv[22]|giv[23]	coref	7-7[0_23]
5-17	380-385	liver	abstract[20]|abstract[22]|object[23]	new[20]|giv[22]|giv[23]	_	_
5-18	386-387	,	abstract[20]	new[20]	_	_
5-19	388-401	significantly	abstract[20]	new[20]	_	_
5-20	402-411	decreases	abstract[20]	new[20]	_	_
5-21	412-414	in	abstract[20]	new[20]	_	_
5-22	415-426	individuals	abstract[20]|person[24]	new[20]|new[24]	_	_
5-23	427-431	with	abstract[20]|person[24]	new[20]|new[24]	_	_
5-24	432-435	and	abstract[20]|person[24]	new[20]|new[24]	_	_
5-25	436-443	without	abstract[20]|person[24]	new[20]|new[24]	_	_
5-26	444-448	T2DM	abstract[20]|person[24]|abstract	new[20]|new[24]|new	coref	40-3
5-27	449-454	after	abstract[20]	new[20]	_	_
5-28	455-456	a	abstract[20]|event[27]	new[20]|new[27]	coref	12-25[0_27]
5-29	457-464	fasting	abstract[20]|event|event[27]	new[20]|giv|new[27]	coref	13-3[83_0]
5-30	465-477	intervention	abstract[20]|event[27]	new[20]|new[27]	_	_
5-31	478-480	of	abstract[20]|event[27]	new[20]|new[27]	_	_
5-32	481-483	at	abstract[20]|event[27]|time[28]	new[20]|new[27]|new[28]	_	_
5-33	484-489	least	abstract[20]|event[27]|time[28]	new[20]|new[27]|new[28]	_	_
5-34	490-491	6	abstract[20]|event[27]|time[28]	new[20]|new[27]|new[28]	_	_
5-35	492-496	days	abstract[20]|event[27]|time[28]	new[20]|new[27]|new[28]	_	_
5-36	497-498	.	_	_	_	_

#Text=The prospective study design according to a standardized protocol with a well-established fasting technique and a close clinical monitoring was a strength of this study .
6-1	499-502	The	abstract[30]	new[30]	coref	6-21[34_30]
6-2	503-514	prospective	abstract[30]	new[30]	_	_
6-3	515-520	study	abstract|abstract[30]	giv|new[30]	coref	6-24[35_0]
6-4	521-527	design	abstract[30]	new[30]	_	_
6-5	528-537	according	abstract[30]	new[30]	_	_
6-6	538-540	to	abstract[30]	new[30]	_	_
6-7	541-542	a	abstract[30]|abstract[31]	new[30]|new[31]	_	_
6-8	543-555	standardized	abstract[30]|abstract[31]	new[30]|new[31]	_	_
6-9	556-564	protocol	abstract[30]|abstract[31]	new[30]|new[31]	_	_
6-10	565-569	with	abstract[30]|abstract[31]	new[30]|new[31]	_	_
6-11	570-571	a	abstract[30]|abstract[31]|abstract[32]	new[30]|new[31]|new[32]	_	_
6-12	572-588	well-established	abstract[30]|abstract[31]|abstract[32]	new[30]|new[31]|new[32]	_	_
6-13	589-596	fasting	abstract[30]|abstract[31]|abstract[32]	new[30]|new[31]|new[32]	_	_
6-14	597-606	technique	abstract[30]|abstract[31]|abstract[32]	new[30]|new[31]|new[32]	_	_
6-15	607-610	and	abstract[30]|abstract[31]	new[30]|new[31]	_	_
6-16	611-612	a	abstract[30]|abstract[31]|event[33]	new[30]|new[31]|new[33]	_	_
6-17	613-618	close	abstract[30]|abstract[31]|event[33]	new[30]|new[31]|new[33]	_	_
6-18	619-627	clinical	abstract[30]|abstract[31]|event[33]	new[30]|new[31]|new[33]	_	_
6-19	628-638	monitoring	abstract[30]|abstract[31]|event[33]	new[30]|new[31]|new[33]	_	_
6-20	639-642	was	_	_	_	_
6-21	643-644	a	abstract[34]	giv[34]	_	_
6-22	645-653	strength	abstract[34]	giv[34]	_	_
6-23	654-656	of	abstract[34]	giv[34]	_	_
6-24	657-661	this	abstract[34]|abstract[35]	giv[34]|giv[35]	coref	18-8[110_35]
6-25	662-667	study	abstract[34]|abstract[35]	giv[34]|giv[35]	_	_
6-26	668-669	.	_	_	_	_

#Text=Weight reduction and improvement of fatty liver indicators are known to be interrelated .
7-1	670-676	Weight	person|abstract[37]	new|new[37]	coref	8-5[43_37]
7-2	677-686	reduction	abstract[37]	new[37]	_	_
7-3	687-690	and	_	_	_	_
7-4	691-702	improvement	abstract[38]	new[38]	_	_
7-5	703-705	of	abstract[38]	new[38]	_	_
7-6	706-711	fatty	abstract[38]|abstract[40]	new[38]|new[40]	_	_
7-7	712-717	liver	abstract[38]|object|abstract[40]	new[38]|giv|new[40]	coref	8-15[46_0]
7-8	718-728	indicators	abstract[38]|abstract[40]	new[38]|new[40]	_	_
7-9	729-732	are	_	_	_	_
7-10	733-738	known	_	_	_	_
7-11	739-741	to	_	_	_	_
7-12	742-744	be	_	_	_	_
7-13	745-757	interrelated	_	_	_	_
7-14	758-759	.	_	_	_	_

#Text=Our results indicate that even a modest reduction of BMI improved surrogate markers of fatty liver .
8-1	760-763	Our	person|abstract[42]	giv|giv[42]	ana	19-1
8-2	764-771	results	abstract[42]	giv[42]	_	_
8-3	772-780	indicate	_	_	_	_
8-4	781-785	that	_	_	_	_
8-5	786-790	even	abstract[43]	giv[43]	_	_
8-6	791-792	a	abstract[43]	giv[43]	_	_
8-7	793-799	modest	abstract[43]	giv[43]	_	_
8-8	800-809	reduction	abstract[43]	giv[43]	_	_
8-9	810-812	of	abstract[43]	giv[43]	_	_
8-10	813-816	BMI	abstract[43]|abstract	giv[43]|new	coref	9-21
8-11	817-825	improved	event|abstract	new|new	coref|none	24-19[148_0]|35-18
8-12	826-835	surrogate	abstract[45]	new[45]	_	_
8-13	836-843	markers	abstract[45]	new[45]	_	_
8-14	844-846	of	abstract[45]	new[45]	_	_
8-15	847-852	fatty	abstract[45]|object[46]	new[45]|giv[46]	_	_
8-16	853-858	liver	abstract[45]|object[46]	new[45]|giv[46]	_	_
8-17	859-860	.	_	_	_	_

#Text=Indeed , in nearly half of the subjects in the highest risk category ( FLI > 60 ) , a BMI reduction of less than 5 % was sufficient to induce a shift to a lower risk category .
9-1	861-867	Indeed	_	_	_	_
9-2	868-869	,	_	_	_	_
9-3	870-872	in	_	_	_	_
9-4	873-879	nearly	abstract[47]	new[47]	_	_
9-5	880-884	half	abstract[47]	new[47]	_	_
9-6	885-887	of	abstract[47]	new[47]	_	_
9-7	888-891	the	abstract[47]|animal[48]	new[47]|new[48]	coref	16-14[93_48]
9-8	892-900	subjects	abstract[47]|animal[48]	new[47]|new[48]	_	_
9-9	901-903	in	abstract[47]|animal[48]	new[47]|new[48]	_	_
9-10	904-907	the	abstract[47]|animal[48]|abstract[50]	new[47]|new[48]|new[50]	_	_
9-11	908-915	highest	abstract[47]|animal[48]|abstract[50]	new[47]|new[48]|new[50]	_	_
9-12	916-920	risk	abstract[47]|animal[48]|abstract|abstract[50]	new[47]|new[48]|new|new[50]	coref	9-37
9-13	921-929	category	abstract[47]|animal[48]|abstract[50]	new[47]|new[48]|new[50]	_	_
9-14	930-931	(	abstract[47]|animal[48]|abstract[50]	new[47]|new[48]|new[50]	_	_
9-15	932-935	FLI	abstract[47]|animal[48]|abstract[50]|abstract	new[47]|new[48]|new[50]|giv	coref	30-20
9-16	936-937	>	abstract[47]|animal[48]|abstract[50]	new[47]|new[48]|new[50]	_	_
9-17	938-940	60	abstract[47]|animal[48]|abstract[50]	new[47]|new[48]|new[50]	_	_
9-18	941-942	)	abstract[47]|animal[48]|abstract[50]	new[47]|new[48]|new[50]	_	_
9-19	943-944	,	_	_	_	_
9-20	945-946	a	abstract[53]	new[53]	coref	21-16[131_53]
9-21	947-950	BMI	abstract|abstract[53]	giv|new[53]	_	_
9-22	951-960	reduction	abstract[53]	new[53]	_	_
9-23	961-963	of	abstract[53]	new[53]	_	_
9-24	964-968	less	abstract[53]|abstract[54]	new[53]|new[54]	_	_
9-25	969-973	than	abstract[53]|abstract[54]	new[53]|new[54]	_	_
9-26	974-975	5	abstract[53]|abstract[54]	new[53]|new[54]	_	_
9-27	976-977	%	abstract[53]|abstract[54]	new[53]|new[54]	_	_
9-28	978-981	was	_	_	_	_
9-29	982-992	sufficient	_	_	_	_
9-30	993-995	to	_	_	_	_
9-31	996-1002	induce	_	_	_	_
9-32	1003-1004	a	event[55]	new[55]	_	_
9-33	1005-1010	shift	event[55]	new[55]	_	_
9-34	1011-1013	to	event[55]	new[55]	_	_
9-35	1014-1015	a	event[55]|abstract[57]	new[55]|new[57]	_	_
9-36	1016-1021	lower	event[55]|abstract[57]	new[55]|new[57]	_	_
9-37	1022-1026	risk	event[55]|abstract|abstract[57]	new[55]|giv|new[57]	_	_
9-38	1027-1035	category	event[55]|abstract[57]	new[55]|new[57]	_	_
9-39	1036-1037	.	_	_	_	_

#Text=In most patients , NAFLD is associated with features of metabolic syndrome , central obesity , elevated blood pressure , dyslipidemia , hyperglycemia , and insulin resistance .
10-1	1038-1040	In	_	_	_	_
10-2	1041-1045	most	person[58]	new[58]	coref	30-26[206_58]
10-3	1046-1054	patients	person[58]	new[58]	_	_
10-4	1055-1056	,	_	_	_	_
10-5	1057-1062	NAFLD	abstract	giv	coref	20-19
10-6	1063-1065	is	_	_	_	_
10-7	1066-1076	associated	_	_	_	_
10-8	1077-1081	with	_	_	_	_
10-9	1082-1090	features	abstract[60]	new[60]	_	_
10-10	1091-1093	of	abstract[60]	new[60]	_	_
10-11	1094-1103	metabolic	abstract[60]|abstract[61]	new[60]|new[61]	_	_
10-12	1104-1112	syndrome	abstract[60]|abstract[61]	new[60]|new[61]	_	_
10-13	1113-1114	,	abstract[60]	new[60]	_	_
10-14	1115-1122	central	abstract[60]|abstract[62]	new[60]|new[62]	coref	28-14[0_62]
10-15	1123-1130	obesity	abstract[60]|abstract[62]	new[60]|new[62]	_	_
10-16	1131-1132	,	abstract[60]	new[60]	_	_
10-17	1133-1141	elevated	abstract[60]|abstract[63]	new[60]|new[63]	_	_
10-18	1142-1147	blood	abstract[60]|abstract[63]	new[60]|new[63]	_	_
10-19	1148-1156	pressure	abstract[60]|abstract[63]	new[60]|new[63]	_	_
10-20	1157-1158	,	abstract[60]	new[60]	_	_
10-21	1159-1171	dyslipidemia	abstract[60]|abstract	new[60]|new	_	_
10-22	1172-1173	,	abstract[60]	new[60]	_	_
10-23	1174-1187	hyperglycemia	abstract[60]|abstract	new[60]|new	_	_
10-24	1188-1189	,	abstract[60]	new[60]	_	_
10-25	1190-1193	and	abstract[60]	new[60]	_	_
10-26	1194-1201	insulin	abstract[60]|substance|abstract[67]	new[60]|new|new[67]	coref|coref	28-16|28-16[185_67]
10-27	1202-1212	resistance	abstract[60]|abstract[67]	new[60]|new[67]	_	_
10-28	1213-1214	.	_	_	_	_

#Text=Although these pathologies can be addressed by lifestyle interventions , in daily life the adherence to the necessary lifestyle changes is poor , resulting in suboptimal outcomes .
11-1	1215-1223	Although	_	_	_	_
11-2	1224-1229	these	abstract[68]	new[68]	_	_
11-3	1230-1241	pathologies	abstract[68]	new[68]	_	_
11-4	1242-1245	can	_	_	_	_
11-5	1246-1248	be	_	_	_	_
11-6	1249-1258	addressed	_	_	_	_
11-7	1259-1261	by	_	_	_	_
11-8	1262-1271	lifestyle	abstract|abstract[70]	new|giv[70]	coref	11-19
11-9	1272-1285	interventions	abstract[70]	giv[70]	_	_
11-10	1286-1287	,	_	_	_	_
11-11	1288-1290	in	_	_	_	_
11-12	1291-1296	daily	abstract[71]	new[71]	_	_
11-13	1297-1301	life	abstract[71]	new[71]	_	_
11-14	1302-1305	the	abstract[72]	new[72]	coref	17-16[103_72]
11-15	1306-1315	adherence	abstract[72]	new[72]	_	_
11-16	1316-1318	to	abstract[72]	new[72]	_	_
11-17	1319-1322	the	abstract[72]|abstract[74]	new[72]|new[74]	_	_
11-18	1323-1332	necessary	abstract[72]|abstract[74]	new[72]|new[74]	_	_
11-19	1333-1342	lifestyle	abstract[72]|abstract|abstract[74]	new[72]|giv|new[74]	coref	17-16
11-20	1343-1350	changes	abstract[72]|abstract[74]	new[72]|new[74]	_	_
11-21	1351-1353	is	_	_	_	_
11-22	1354-1358	poor	_	_	_	_
11-23	1359-1360	,	_	_	_	_
11-24	1361-1370	resulting	_	_	_	_
11-25	1371-1373	in	_	_	_	_
11-26	1374-1384	suboptimal	abstract[75]	new[75]	coref	17-12[101_75]
11-27	1385-1393	outcomes	abstract[75]	new[75]	_	_
11-28	1394-1395	.	_	_	_	_

#Text=In contrast , in pragmatic programs there is a greater benefit in a more substantial weight loss , particularly at early stages of the intervention period .
12-1	1396-1398	In	_	_	_	_
12-2	1399-1407	contrast	_	_	_	_
12-3	1408-1409	,	_	_	_	_
12-4	1410-1412	in	_	_	_	_
12-5	1413-1422	pragmatic	abstract[76]	new[76]	_	_
12-6	1423-1431	programs	abstract[76]	new[76]	_	_
12-7	1432-1437	there	_	_	_	_
12-8	1438-1440	is	_	_	_	_
12-9	1441-1442	a	abstract[77]	new[77]	_	_
12-10	1443-1450	greater	abstract[77]	new[77]	_	_
12-11	1451-1458	benefit	abstract[77]	new[77]	_	_
12-12	1459-1461	in	abstract[77]	new[77]	_	_
12-13	1462-1463	a	abstract[77]|event[79]	new[77]|new[79]	coref	24-5[144_79]
12-14	1464-1468	more	abstract[77]|event[79]	new[77]|new[79]	_	_
12-15	1469-1480	substantial	abstract[77]|event[79]	new[77]|new[79]	_	_
12-16	1481-1487	weight	abstract[77]|abstract|event[79]	new[77]|giv|new[79]	coref	13-8
12-17	1488-1492	loss	abstract[77]|event[79]	new[77]|new[79]	_	_
12-18	1493-1494	,	_	_	_	_
12-19	1495-1507	particularly	time[80]	new[80]	_	_
12-20	1508-1510	at	time[80]	new[80]	_	_
12-21	1511-1516	early	time[80]	new[80]	_	_
12-22	1517-1523	stages	time[80]	new[80]	_	_
12-23	1524-1526	of	time[80]	new[80]	_	_
12-24	1527-1530	the	time[80]|time[82]	new[80]|new[82]	coref	28-7[181_82]
12-25	1531-1543	intervention	time[80]|event|time[82]	new[80]|giv|new[82]	coref	19-7[117_0]
12-26	1544-1550	period	time[80]|time[82]	new[80]|new[82]	_	_
12-27	1551-1552	.	_	_	_	_

#Text=Hence , periodic fasting can significantly reduce weight , and this effect can be maintained over time .
13-1	1553-1558	Hence	_	_	_	_
13-2	1559-1560	,	_	_	_	_
13-3	1561-1569	periodic	event[83]	giv[83]	coref	16-18[94_83]
13-4	1570-1577	fasting	event[83]	giv[83]	_	_
13-5	1578-1581	can	_	_	_	_
13-6	1582-1595	significantly	_	_	_	_
13-7	1596-1602	reduce	_	_	_	_
13-8	1603-1609	weight	abstract	giv	coref	21-10
13-9	1610-1611	,	_	_	_	_
13-10	1612-1615	and	_	_	_	_
13-11	1616-1620	this	abstract[85]	new[85]	_	_
13-12	1621-1627	effect	abstract[85]	new[85]	_	_
13-13	1628-1631	can	_	_	_	_
13-14	1632-1634	be	_	_	_	_
13-15	1635-1645	maintained	_	_	_	_
13-16	1646-1650	over	_	_	_	_
13-17	1651-1655	time	_	_	_	_
13-18	1656-1657	.	_	_	_	_

#Text=There are several concerns about the adverse effects of fasting .
14-1	1658-1663	There	_	_	_	_
14-2	1664-1667	are	_	_	_	_
14-3	1668-1675	several	abstract[86]	new[86]	_	_
14-4	1676-1684	concerns	abstract[86]	new[86]	_	_
14-5	1685-1690	about	abstract[86]	new[86]	_	_
14-6	1691-1694	the	abstract[86]|abstract[87]	new[86]|new[87]	coref	17-10[100_87]
14-7	1695-1702	adverse	abstract[86]|abstract[87]	new[86]|new[87]	_	_
14-8	1703-1710	effects	abstract[86]|abstract[87]	new[86]|new[87]	_	_
14-9	1711-1713	of	abstract[86]|abstract[87]	new[86]|new[87]	_	_
14-10	1714-1721	fasting	abstract[86]|abstract[87]	new[86]|new[87]	_	_
14-11	1722-1723	.	_	_	_	_

#Text=Several non-fatal ( e.g. , headache ) and rarely fatal ( e.g. , ventricular arrhythmia ) events have been reported .
15-1	1724-1731	Several	event[90]	new[90]	coref	16-4[91_90]
15-2	1732-1741	non-fatal	event[90]	new[90]	_	_
15-3	1742-1743	(	event[90]	new[90]	_	_
15-4	1744-1748	e.g.	abstract[88]|event[90]	new[88]|new[90]	_	_
15-5	1749-1750	,	abstract[88]|event[90]	new[88]|new[90]	_	_
15-6	1751-1759	headache	abstract[88]|event[90]	new[88]|new[90]	_	_
15-7	1760-1761	)	event[90]	new[90]	_	_
15-8	1762-1765	and	event[90]	new[90]	_	_
15-9	1766-1772	rarely	event[90]	new[90]	_	_
15-10	1773-1778	fatal	event[90]	new[90]	_	_
15-11	1779-1780	(	event[90]	new[90]	_	_
15-12	1781-1785	e.g.	abstract[89]|event[90]	new[89]|new[90]	_	_
15-13	1786-1787	,	abstract[89]|event[90]	new[89]|new[90]	_	_
15-14	1788-1799	ventricular	abstract[89]|event[90]	new[89]|new[90]	_	_
15-15	1800-1810	arrhythmia	abstract[89]|event[90]	new[89]|new[90]	_	_
15-16	1811-1812	)	event[90]	new[90]	_	_
15-17	1813-1819	events	event[90]	new[90]	_	_
15-18	1820-1824	have	_	_	_	_
15-19	1825-1829	been	_	_	_	_
15-20	1830-1838	reported	_	_	_	_
15-21	1839-1840	.	_	_	_	_

#Text=In contrast , no severe adverse events were found in a cohort of 1422 subjects treated with a periodic fasting lasting 4 – 21 days , .
16-1	1841-1843	In	_	_	_	_
16-2	1844-1852	contrast	_	_	_	_
16-3	1853-1854	,	_	_	_	_
16-4	1855-1857	no	event[91]	giv[91]	coref	18-3[108_91]
16-5	1858-1864	severe	event[91]	giv[91]	_	_
16-6	1865-1872	adverse	event[91]	giv[91]	_	_
16-7	1873-1879	events	event[91]	giv[91]	_	_
16-8	1880-1884	were	_	_	_	_
16-9	1885-1890	found	_	_	_	_
16-10	1891-1893	in	_	_	_	_
16-11	1894-1895	a	person[92]	new[92]	_	_
16-12	1896-1902	cohort	person[92]	new[92]	_	_
16-13	1903-1905	of	person[92]	new[92]	_	_
16-14	1906-1910	1422	person[92]|animal[93]	new[92]|giv[93]	_	_
16-15	1911-1919	subjects	person[92]|animal[93]	new[92]|giv[93]	_	_
16-16	1920-1927	treated	person[92]|animal[93]	new[92]|giv[93]	_	_
16-17	1928-1932	with	person[92]|animal[93]	new[92]|giv[93]	_	_
16-18	1933-1934	a	person[92]|animal[93]|event[94]	new[92]|giv[93]|giv[94]	coref	17-19[0_94]
16-19	1935-1943	periodic	person[92]|animal[93]|event[94]	new[92]|giv[93]|giv[94]	_	_
16-20	1944-1951	fasting	person[92]|animal[93]|event[94]	new[92]|giv[93]|giv[94]	_	_
16-21	1952-1959	lasting	person[92]|animal[93]|event[94]	new[92]|giv[93]|giv[94]	_	_
16-22	1960-1961	4	person[92]|animal[93]|event[94]|time[95]	new[92]|giv[93]|giv[94]|new[95]	_	_
16-23	1962-1963	–	person[92]|animal[93]|event[94]|time[95]	new[92]|giv[93]|giv[94]|new[95]	_	_
16-24	1964-1966	21	person[92]|animal[93]|event[94]|time[95]	new[92]|giv[93]|giv[94]|new[95]	_	_
16-25	1967-1971	days	person[92]|animal[93]|event[94]|time[95]	new[92]|giv[93]|giv[94]|new[95]	_	_
16-26	1972-1973	,	_	_	_	_
16-27	1974-1975	.	_	_	_	_

#Text=Michalsen et al. evaluated the acceptance , safety , effects on health-related outcomes , and lifestyle adherence of fasting therapy in different chronic internal diseases .
17-1	1976-1985	Michalsen	person	new	_	_
17-2	1986-1988	et	_	_	_	_
17-3	1989-1992	al.	_	_	_	_
17-4	1993-2002	evaluated	_	_	_	_
17-5	2003-2006	the	abstract[97]|abstract[98]	new[97]|new[98]	ana	18-1[0_98]
17-6	2007-2017	acceptance	abstract[97]|abstract[98]	new[97]|new[98]	_	_
17-7	2018-2019	,	abstract[98]	new[98]	_	_
17-8	2020-2026	safety	abstract[98]|abstract	new[98]|new	_	_
17-9	2027-2028	,	abstract[98]	new[98]	_	_
17-10	2029-2036	effects	abstract[98]|abstract[100]	new[98]|giv[100]	_	_
17-11	2037-2039	on	abstract[98]|abstract[100]	new[98]|giv[100]	_	_
17-12	2040-2054	health-related	abstract[98]|abstract[100]|abstract[101]	new[98]|giv[100]|giv[101]	_	_
17-13	2055-2063	outcomes	abstract[98]|abstract[100]|abstract[101]	new[98]|giv[100]|giv[101]	_	_
17-14	2064-2065	,	abstract[98]	new[98]	_	_
17-15	2066-2069	and	abstract[98]	new[98]	_	_
17-16	2070-2079	lifestyle	abstract[98]|abstract|abstract[103]	new[98]|giv|giv[103]	_	_
17-17	2080-2089	adherence	abstract[98]|abstract[103]	new[98]|giv[103]	_	_
17-18	2090-2092	of	abstract[98]|abstract[103]	new[98]|giv[103]	_	_
17-19	2093-2100	fasting	abstract[98]|abstract[103]|event|abstract[105]	new[98]|giv[103]|giv|new[105]	coref|coref	19-7|19-7[115_105]
17-20	2101-2108	therapy	abstract[98]|abstract[103]|abstract[105]	new[98]|giv[103]|new[105]	_	_
17-21	2109-2111	in	abstract[98]|abstract[103]|abstract[105]	new[98]|giv[103]|new[105]	_	_
17-22	2112-2121	different	abstract[98]|abstract[103]|abstract[105]|abstract[106]	new[98]|giv[103]|new[105]|new[106]	_	_
17-23	2122-2129	chronic	abstract[98]|abstract[103]|abstract[105]|abstract[106]	new[98]|giv[103]|new[105]|new[106]	_	_
17-24	2130-2138	internal	abstract[98]|abstract[103]|abstract[105]|abstract[106]	new[98]|giv[103]|new[105]|new[106]	_	_
17-25	2139-2147	diseases	abstract[98]|abstract[103]|abstract[105]|abstract[106]	new[98]|giv[103]|new[105]|new[106]	_	_
17-26	2148-2149	.	_	_	_	_

#Text=They found no serious adverse events throughout their study .
18-1	2150-2154	They	abstract	giv	ana	18-8
18-2	2155-2160	found	_	_	_	_
18-3	2161-2163	no	event[108]	giv[108]	_	_
18-4	2164-2171	serious	event[108]	giv[108]	_	_
18-5	2172-2179	adverse	event[108]	giv[108]	_	_
18-6	2180-2186	events	event[108]	giv[108]	_	_
18-7	2187-2197	throughout	_	_	_	_
18-8	2198-2203	their	abstract|abstract[110]	giv|giv[110]	coref	19-1[112_110]
18-9	2204-2209	study	abstract[110]	giv[110]	_	_
18-10	2210-2211	.	_	_	_	_

#Text=Our study supports the hypothesis that fasting therapy provided in a controlled clinical setting is a safe intervention .
19-1	2212-2215	Our	person|abstract[112]	giv|giv[112]	ana	30-1
19-2	2216-2221	study	abstract[112]	giv[112]	_	_
19-3	2222-2230	supports	_	_	_	_
19-4	2231-2234	the	abstract[113]	giv[113]	_	_
19-5	2235-2245	hypothesis	abstract[113]	giv[113]	_	_
19-6	2246-2250	that	abstract[113]	giv[113]	_	_
19-7	2251-2258	fasting	abstract[113]|event|abstract[115]|event[117]	giv[113]|giv|giv[115]|giv[117]	coref|coref	23-5[140_0]|33-4[213_115]
19-8	2259-2266	therapy	abstract[113]|abstract[115]|event[117]	giv[113]|giv[115]|giv[117]	_	_
19-9	2267-2275	provided	abstract[113]|abstract[115]|event[117]	giv[113]|giv[115]|giv[117]	_	_
19-10	2276-2278	in	abstract[113]|abstract[115]|event[117]	giv[113]|giv[115]|giv[117]	_	_
19-11	2279-2280	a	abstract[113]|abstract[115]|abstract[116]|event[117]	giv[113]|giv[115]|new[116]|giv[117]	_	_
19-12	2281-2291	controlled	abstract[113]|abstract[115]|abstract[116]|event[117]	giv[113]|giv[115]|new[116]|giv[117]	_	_
19-13	2292-2300	clinical	abstract[113]|abstract[115]|abstract[116]|event[117]	giv[113]|giv[115]|new[116]|giv[117]	_	_
19-14	2301-2308	setting	abstract[113]|abstract[115]|abstract[116]|event[117]	giv[113]|giv[115]|new[116]|giv[117]	_	_
19-15	2309-2311	is	abstract[113]|event[117]	giv[113]|giv[117]	_	_
19-16	2312-2313	a	abstract[113]|event[117]	giv[113]|giv[117]	_	_
19-17	2314-2318	safe	abstract[113]|event[117]	giv[113]|giv[117]	_	_
19-18	2319-2331	intervention	abstract[113]|event[117]	giv[113]|giv[117]	_	_
19-19	2332-2333	.	_	_	_	_

#Text=There is a large body of evidence on the beneficial effects of carbohydrate restriction and hypocaloric diets on NAFLD .
20-1	2334-2339	There	_	_	_	_
20-2	2340-2342	is	_	_	_	_
20-3	2343-2344	a	object[118]	giv[118]	_	_
20-4	2345-2350	large	object[118]	giv[118]	_	_
20-5	2351-2355	body	object[118]	giv[118]	_	_
20-6	2356-2358	of	object[118]	giv[118]	_	_
20-7	2359-2367	evidence	object[118]|abstract[119]	giv[118]|giv[119]	ana	21-1[0_119]
20-8	2368-2370	on	object[118]|abstract[119]	giv[118]|giv[119]	_	_
20-9	2371-2374	the	object[118]|abstract[119]|abstract[120]	giv[118]|giv[119]|new[120]	coref	24-4[145_120]
20-10	2375-2385	beneficial	object[118]|abstract[119]|abstract[120]	giv[118]|giv[119]|new[120]	_	_
20-11	2386-2393	effects	object[118]|abstract[119]|abstract[120]	giv[118]|giv[119]|new[120]	_	_
20-12	2394-2396	of	object[118]|abstract[119]|abstract[120]	giv[118]|giv[119]|new[120]	_	_
20-13	2397-2409	carbohydrate	object[118]|abstract[119]|abstract[120]|substance|abstract[122]	giv[118]|giv[119]|new[120]|new|new[122]	coref|coref	22-5|22-5[135_122]
20-14	2410-2421	restriction	object[118]|abstract[119]|abstract[120]|abstract[122]	giv[118]|giv[119]|new[120]|new[122]	_	_
20-15	2422-2425	and	object[118]|abstract[119]|abstract[120]	giv[118]|giv[119]|new[120]	_	_
20-16	2426-2437	hypocaloric	object[118]|abstract[119]|abstract[120]|abstract[123]	giv[118]|giv[119]|new[120]|new[123]	_	_
20-17	2438-2443	diets	object[118]|abstract[119]|abstract[120]|abstract[123]	giv[118]|giv[119]|new[120]|new[123]	_	_
20-18	2444-2446	on	_	_	_	_
20-19	2447-2452	NAFLD	abstract	giv	coref	29-28
20-20	2453-2454	.	_	_	_	_

#Text=It has also been shown that-at equal levels of weight reduction-a carbohydrate-restricted diet leads to a significantly greater intrahepatic triglyceride reduction than low-calorie diet alone .
21-1	2455-2457	It	abstract	giv	coref	29-4[187_0]
21-2	2458-2461	has	_	_	_	_
21-3	2462-2466	also	_	_	_	_
21-4	2467-2471	been	_	_	_	_
21-5	2472-2477	shown	_	_	_	_
21-6	2478-2485	that-at	_	_	_	_
21-7	2486-2491	equal	abstract[126]	new[126]	coref	33-22[219_126]
21-8	2492-2498	levels	abstract[126]	new[126]	_	_
21-9	2499-2501	of	abstract[126]	new[126]	_	_
21-10	2502-2508	weight	abstract[126]|abstract|event[128]	new[126]|giv|new[128]	_	_
21-11	2509-2520	reduction-a	abstract[126]|event[128]	new[126]|new[128]	_	_
21-12	2521-2544	carbohydrate-restricted	abstract[129]	new[129]	_	_
21-13	2545-2549	diet	abstract[129]	new[129]	_	_
21-14	2550-2555	leads	_	_	_	_
21-15	2556-2558	to	_	_	_	_
21-16	2559-2560	a	abstract[131]	giv[131]	_	_
21-17	2561-2574	significantly	abstract[131]	giv[131]	_	_
21-18	2575-2582	greater	abstract[131]	giv[131]	_	_
21-19	2583-2595	intrahepatic	abstract[131]	giv[131]	_	_
21-20	2596-2608	triglyceride	substance|abstract[131]	new|giv[131]	_	_
21-21	2609-2618	reduction	abstract[131]	giv[131]	_	_
21-22	2619-2623	than	_	_	_	_
21-23	2624-2635	low-calorie	substance[132]	new[132]	_	_
21-24	2636-2640	diet	substance[132]	new[132]	_	_
21-25	2641-2646	alone	substance[132]	new[132]	_	_
21-26	2647-2648	.	_	_	_	_

#Text=The metabolic advantage of carbohydrate restriction appears to be related to a more pronounced lipid oxidation and enhanced ketogenesis .
22-1	2649-2652	The	abstract[133]	new[133]	_	_
22-2	2653-2662	metabolic	abstract[133]	new[133]	_	_
22-3	2663-2672	advantage	abstract[133]	new[133]	_	_
22-4	2673-2675	of	abstract[133]	new[133]	_	_
22-5	2676-2688	carbohydrate	abstract[133]|substance|abstract[135]	new[133]|giv|giv[135]	coref	23-16[143_135]
22-6	2689-2700	restriction	abstract[133]|abstract[135]	new[133]|giv[135]	_	_
22-7	2701-2708	appears	_	_	_	_
22-8	2709-2711	to	_	_	_	_
22-9	2712-2714	be	_	_	_	_
22-10	2715-2722	related	_	_	_	_
22-11	2723-2725	to	_	_	_	_
22-12	2726-2727	a	abstract[137]	new[137]	_	_
22-13	2728-2732	more	abstract[137]	new[137]	_	_
22-14	2733-2743	pronounced	abstract[137]	new[137]	_	_
22-15	2744-2749	lipid	substance|abstract[137]	new|new[137]	coref	24-22
22-16	2750-2759	oxidation	abstract[137]	new[137]	_	_
22-17	2760-2763	and	_	_	_	_
22-18	2764-2772	enhanced	substance[138]	new[138]	coref	28-3[0_138]
22-19	2773-2784	ketogenesis	substance[138]	new[138]	_	_
22-20	2785-2786	.	_	_	_	_

#Text=In recent years , intermittent and periodic fasting has gained popularity as an alternative to continuous caloric restriction .
23-1	2787-2789	In	_	_	_	_
23-2	2790-2796	recent	time[139]	new[139]	_	_
23-3	2797-2802	years	time[139]	new[139]	_	_
23-4	2803-2804	,	_	_	_	_
23-5	2805-2817	intermittent	event[140]	giv[140]	coref	24-9[146_140]
23-6	2818-2821	and	event[140]	giv[140]	_	_
23-7	2822-2830	periodic	event[140]	giv[140]	_	_
23-8	2831-2838	fasting	event[140]	giv[140]	_	_
23-9	2839-2842	has	_	_	_	_
23-10	2843-2849	gained	_	_	_	_
23-11	2850-2860	popularity	abstract	new	_	_
23-12	2861-2863	as	_	_	_	_
23-13	2864-2866	an	abstract[142]	new[142]	_	_
23-14	2867-2878	alternative	abstract[142]	new[142]	_	_
23-15	2879-2881	to	abstract[142]	new[142]	_	_
23-16	2882-2892	continuous	abstract[142]|abstract[143]	new[142]|giv[143]	_	_
23-17	2893-2900	caloric	abstract[142]|abstract[143]	new[142]|giv[143]	_	_
23-18	2901-2912	restriction	abstract[142]|abstract[143]	new[142]|giv[143]	_	_
23-19	2913-2914	.	_	_	_	_

#Text=In addition to the weight loss effects , periodic fasting is associated with several metabolic benefits , including the improvement of lipid profiles .
24-1	2915-2917	In	_	_	_	_
24-2	2918-2926	addition	_	_	_	_
24-3	2927-2929	to	_	_	_	_
24-4	2930-2933	the	abstract[145]	giv[145]	coref	26-8[155_145]
24-5	2934-2940	weight	event[144]|abstract[145]	giv[144]|giv[145]	_	_
24-6	2941-2945	loss	event[144]|abstract[145]	giv[144]|giv[145]	_	_
24-7	2946-2953	effects	abstract[145]	giv[145]	_	_
24-8	2954-2955	,	_	_	_	_
24-9	2956-2964	periodic	event[146]	giv[146]	coref	25-7[152_146]
24-10	2965-2972	fasting	event[146]	giv[146]	_	_
24-11	2973-2975	is	_	_	_	_
24-12	2976-2986	associated	_	_	_	_
24-13	2987-2991	with	_	_	_	_
24-14	2992-2999	several	abstract[147]	new[147]	_	_
24-15	3000-3009	metabolic	abstract[147]	new[147]	_	_
24-16	3010-3018	benefits	abstract[147]	new[147]	_	_
24-17	3019-3020	,	abstract[147]	new[147]	_	_
24-18	3021-3030	including	abstract[147]	new[147]	_	_
24-19	3031-3034	the	abstract[147]|event[148]	new[147]|new[148]	ana	25-1[0_148]
24-20	3035-3046	improvement	abstract[147]|event[148]	new[147]|new[148]	_	_
24-21	3047-3049	of	abstract[147]|event[148]	new[147]|new[148]	_	_
24-22	3050-3055	lipid	abstract[147]|event[148]|substance|abstract[150]	new[147]|new[148]|giv|new[150]	coref	26-35
24-23	3056-3064	profiles	abstract[147]|event[148]|abstract[150]	new[147]|new[148]|new[150]	_	_
24-24	3065-3066	.	_	_	_	_

#Text=This has been also shown for intermittent fasting , e.g. , Ramadan fasting .
25-1	3067-3071	This	event	giv	_	_
25-2	3072-3075	has	_	_	_	_
25-3	3076-3080	been	_	_	_	_
25-4	3081-3085	also	_	_	_	_
25-5	3086-3091	shown	_	_	_	_
25-6	3092-3095	for	_	_	_	_
25-7	3096-3108	intermittent	event[152]	giv[152]	coref	30-7[199_152]
25-8	3109-3116	fasting	event[152]	giv[152]	_	_
25-9	3117-3118	,	_	_	_	_
25-10	3119-3123	e.g.	_	_	_	_
25-11	3124-3125	,	_	_	_	_
25-12	3126-3133	Ramadan	person	new	_	_
25-13	3134-3141	fasting	_	_	_	_
25-14	3142-3143	.	_	_	_	_

#Text=The key mechanism responsible for many of these beneficial effects is the metabolic switch from the utilization of glycogenolysis-derived glucose to fatty acids and fatty acid-derived ketones , i.e. , a fundamental switch from lipid synthesis and fat storage to mobilization of fat in the form of free fatty acids and fatty acid-derived ketones .
26-1	3144-3147	The	event[154]	new[154]	coref	26-12[156_154]
26-2	3148-3151	key	event[154]	new[154]	_	_
26-3	3152-3161	mechanism	event[154]	new[154]	_	_
26-4	3162-3173	responsible	event[154]	new[154]	_	_
26-5	3174-3177	for	event[154]	new[154]	_	_
26-6	3178-3182	many	event[154]	new[154]	_	_
26-7	3183-3185	of	_	_	_	_
26-8	3186-3191	these	abstract[155]	giv[155]	_	_
26-9	3192-3202	beneficial	abstract[155]	giv[155]	_	_
26-10	3203-3210	effects	abstract[155]	giv[155]	_	_
26-11	3211-3213	is	_	_	_	_
26-12	3214-3217	the	event[156]	giv[156]	coref	26-29[163_156]
26-13	3218-3227	metabolic	event[156]	giv[156]	_	_
26-14	3228-3234	switch	event[156]	giv[156]	_	_
26-15	3235-3239	from	event[156]	giv[156]	_	_
26-16	3240-3243	the	event[156]|abstract[157]	giv[156]|new[157]	_	_
26-17	3244-3255	utilization	event[156]|abstract[157]	giv[156]|new[157]	_	_
26-18	3256-3258	of	event[156]|abstract[157]	giv[156]|new[157]	_	_
26-19	3259-3281	glycogenolysis-derived	event[156]|abstract[157]|substance[158]	giv[156]|new[157]|new[158]	_	_
26-20	3282-3289	glucose	event[156]|abstract[157]|substance[158]	giv[156]|new[157]|new[158]	_	_
26-21	3290-3292	to	event[156]	giv[156]	_	_
26-22	3293-3298	fatty	event[156]|abstract|substance[160]|substance[161]	giv[156]|new|new[160]|new[161]	coref|coref|coref	26-49|26-48[171_160]|26-48[172_161]
26-23	3299-3304	acids	event[156]|substance[160]|substance[161]	giv[156]|new[160]|new[161]	_	_
26-24	3305-3308	and	event[156]|substance[161]	giv[156]|new[161]	_	_
26-25	3309-3314	fatty	event[156]|substance[161]|substance[162]	giv[156]|new[161]|new[162]	coref	26-52[173_162]
26-26	3315-3327	acid-derived	event[156]|substance[161]|substance[162]	giv[156]|new[161]|new[162]	_	_
26-27	3328-3335	ketones	event[156]|substance[161]|substance[162]	giv[156]|new[161]|new[162]	_	_
26-28	3336-3337	,	_	_	_	_
26-29	3338-3342	i.e.	event[163]	giv[163]	ana	27-1[0_163]
26-30	3343-3344	,	event[163]	giv[163]	_	_
26-31	3345-3346	a	event[163]	giv[163]	_	_
26-32	3347-3358	fundamental	event[163]	giv[163]	_	_
26-33	3359-3365	switch	event[163]	giv[163]	_	_
26-34	3366-3370	from	event[163]	giv[163]	_	_
26-35	3371-3376	lipid	event[163]|substance|abstract[165]	giv[163]|giv|new[165]	coref	43-22
26-36	3377-3386	synthesis	event[163]|abstract[165]	giv[163]|new[165]	_	_
26-37	3387-3390	and	event[163]	giv[163]	_	_
26-38	3391-3394	fat	event[163]|event[166]	giv[163]|new[166]	_	_
26-39	3395-3402	storage	event[163]|event[166]	giv[163]|new[166]	_	_
26-40	3403-3405	to	event[163]	giv[163]	_	_
26-41	3406-3418	mobilization	event[163]|abstract[167]	giv[163]|new[167]	_	_
26-42	3419-3421	of	event[163]|abstract[167]	giv[163]|new[167]	_	_
26-43	3422-3425	fat	event[163]|abstract[167]|substance[168]	giv[163]|new[167]|new[168]	coref	30-14[202_168]
26-44	3426-3428	in	event[163]|abstract[167]|substance[168]	giv[163]|new[167]|new[168]	_	_
26-45	3429-3432	the	event[163]|abstract[167]|substance[168]|abstract[169]	giv[163]|new[167]|new[168]|new[169]	_	_
26-46	3433-3437	form	event[163]|abstract[167]|substance[168]|abstract[169]	giv[163]|new[167]|new[168]|new[169]	_	_
26-47	3438-3440	of	event[163]|abstract[167]|substance[168]|abstract[169]	giv[163]|new[167]|new[168]|new[169]	_	_
26-48	3441-3445	free	event[163]|abstract[167]|substance[168]|abstract[169]|substance[171]|substance[172]	giv[163]|new[167]|new[168]|new[169]|giv[171]|giv[172]	_	_
26-49	3446-3451	fatty	event[163]|abstract[167]|substance[168]|abstract[169]|abstract|substance[171]|substance[172]	giv[163]|new[167]|new[168]|new[169]|giv|giv[171]|giv[172]	coref	35-21
26-50	3452-3457	acids	event[163]|abstract[167]|substance[168]|abstract[169]|substance[171]|substance[172]	giv[163]|new[167]|new[168]|new[169]|giv[171]|giv[172]	_	_
26-51	3458-3461	and	event[163]|abstract[167]|substance[168]|abstract[169]|substance[172]	giv[163]|new[167]|new[168]|new[169]|giv[172]	_	_
26-52	3462-3467	fatty	event[163]|abstract[167]|substance[168]|abstract[169]|substance[172]|substance[173]	giv[163]|new[167]|new[168]|new[169]|giv[172]|giv[173]	_	_
26-53	3468-3480	acid-derived	event[163]|abstract[167]|substance[168]|abstract[169]|substance[172]|substance[173]	giv[163]|new[167]|new[168]|new[169]|giv[172]|giv[173]	_	_
26-54	3481-3488	ketones	event[163]|abstract[167]|substance[168]|abstract[169]|substance[172]|substance[173]	giv[163]|new[167]|new[168]|new[169]|giv[172]|giv[173]	_	_
26-55	3489-3490	.	_	_	_	_

#Text=This occurs between 12 and 36 hours after cessation of food consumption .
27-1	3491-3495	This	event	giv	_	_
27-2	3496-3502	occurs	_	_	_	_
27-3	3503-3510	between	_	_	_	_
27-4	3511-3513	12	time[175]	new[175]	_	_
27-5	3514-3517	and	time[175]	new[175]	_	_
27-6	3518-3520	36	time[175]	new[175]	_	_
27-7	3521-3526	hours	time[175]	new[175]	_	_
27-8	3527-3532	after	_	_	_	_
27-9	3533-3542	cessation	event[176]	new[176]	_	_
27-10	3543-3545	of	event[176]	new[176]	_	_
27-11	3546-3550	food	event[176]|substance|event[178]	new[176]|new|new[178]	_	_
27-12	3551-3562	consumption	event[176]|event[178]	new[176]|new[178]	_	_
27-13	3563-3564	.	_	_	_	_

#Text=Hyperinsulinemia suppresses ketogenesis and therefore prolongs the time to switch in cases of obesity , insulin resistance , and T2DM .
28-1	3565-3581	Hyperinsulinemia	abstract	new	_	_
28-2	3582-3592	suppresses	_	_	_	_
28-3	3593-3604	ketogenesis	substance	giv	coref	29-7[188_0]
28-4	3605-3608	and	_	_	_	_
28-5	3609-3618	therefore	_	_	_	_
28-6	3619-3627	prolongs	_	_	_	_
28-7	3628-3631	the	time[181]	giv[181]	_	_
28-8	3632-3636	time	time[181]	giv[181]	_	_
28-9	3637-3639	to	time[181]	giv[181]	_	_
28-10	3640-3646	switch	time[181]	giv[181]	_	_
28-11	3647-3649	in	time[181]	giv[181]	_	_
28-12	3650-3655	cases	time[181]|event[182]	giv[181]|new[182]	_	_
28-13	3656-3658	of	time[181]|event[182]	giv[181]|new[182]	_	_
28-14	3659-3666	obesity	time[181]|event[182]|abstract	giv[181]|new[182]|giv	_	_
28-15	3667-3668	,	time[181]|event[182]	giv[181]|new[182]	_	_
28-16	3669-3676	insulin	time[181]|event[182]|substance|abstract[185]	giv[181]|new[182]|giv|giv[185]	coref|coref	38-5|38-5[242_185]
28-17	3677-3687	resistance	time[181]|event[182]|abstract[185]	giv[181]|new[182]|giv[185]	_	_
28-18	3688-3689	,	time[181]|event[182]	giv[181]|new[182]	_	_
28-19	3690-3693	and	time[181]|event[182]	giv[181]|new[182]	_	_
28-20	3694-3698	T2DM	time[181]|event[182]|abstract	giv[181]|new[182]|new	coref	38-8
28-21	3699-3700	.	_	_	_	_

#Text=Although there is some evidence of impaired ketogenesis during the progression of liver disease to steatohepatitis , therapies that increase hepatic ketogenesis are expected nonetheless to ameliorate NAFLD .
29-1	3701-3709	Although	_	_	_	_
29-2	3710-3715	there	_	_	_	_
29-3	3716-3718	is	_	_	_	_
29-4	3719-3723	some	abstract[187]	giv[187]	coref	30-4[198_187]
29-5	3724-3732	evidence	abstract[187]	giv[187]	_	_
29-6	3733-3735	of	abstract[187]	giv[187]	_	_
29-7	3736-3744	impaired	abstract[187]|substance[188]	giv[187]|giv[188]	coref	29-21[194_188]
29-8	3745-3756	ketogenesis	abstract[187]|substance[188]	giv[187]|giv[188]	_	_
29-9	3757-3763	during	abstract[187]|substance[188]	giv[187]|giv[188]	_	_
29-10	3764-3767	the	abstract[187]|substance[188]|event[189]	giv[187]|giv[188]|new[189]	_	_
29-11	3768-3779	progression	abstract[187]|substance[188]|event[189]	giv[187]|giv[188]|new[189]	_	_
29-12	3780-3782	of	abstract[187]|substance[188]|event[189]	giv[187]|giv[188]|new[189]	_	_
29-13	3783-3788	liver	abstract[187]|substance[188]|event[189]|object|abstract[191]	giv[187]|giv[188]|new[189]|new|new[191]	coref	30-14
29-14	3789-3796	disease	abstract[187]|substance[188]|event[189]|abstract[191]	giv[187]|giv[188]|new[189]|new[191]	_	_
29-15	3797-3799	to	abstract[187]|substance[188]|event[189]|abstract[191]	giv[187]|giv[188]|new[189]|new[191]	_	_
29-16	3800-3815	steatohepatitis	abstract[187]|substance[188]|event[189]|abstract[191]|abstract	giv[187]|giv[188]|new[189]|new[191]|new	_	_
29-17	3816-3817	,	_	_	_	_
29-18	3818-3827	therapies	event[193]	new[193]	_	_
29-19	3828-3832	that	event[193]	new[193]	_	_
29-20	3833-3841	increase	event[193]|abstract	new[193]|new	none|none	29-20[0_225]|30-22
29-21	3842-3849	hepatic	event[193]|substance[194]	new[193]|giv[194]	_	_
29-22	3850-3861	ketogenesis	event[193]|substance[194]	new[193]|giv[194]	_	_
29-23	3862-3865	are	_	_	_	_
29-24	3866-3874	expected	_	_	_	_
29-25	3875-3886	nonetheless	_	_	_	_
29-26	3887-3889	to	_	_	_	_
29-27	3890-3900	ameliorate	_	_	_	_
29-28	3901-3906	NAFLD	abstract	giv	coref	30-28
29-29	3907-3908	.	_	_	_	_

#Text=Our data provided first evidence that periodic fasting leads to a clearance of liver fat : fasting significantly reduced FLI and increased the proportion of patients without NAFLD ( FLI < 30 units ;
30-1	3909-3912	Our	person|abstract[197]	giv|new[197]	ana	40-16
30-2	3913-3917	data	abstract[197]	new[197]	_	_
30-3	3918-3926	provided	_	_	_	_
30-4	3927-3932	first	abstract[198]	giv[198]	_	_
30-5	3933-3941	evidence	abstract[198]	giv[198]	_	_
30-6	3942-3946	that	abstract[198]	giv[198]	_	_
30-7	3947-3955	periodic	abstract[198]|event[199]	giv[198]|giv[199]	coref	30-17[0_199]
30-8	3956-3963	fasting	abstract[198]|event[199]	giv[198]|giv[199]	_	_
30-9	3964-3969	leads	abstract[198]	giv[198]	_	_
30-10	3970-3972	to	abstract[198]	giv[198]	_	_
30-11	3973-3974	a	abstract[198]|abstract[200]	giv[198]|new[200]	_	_
30-12	3975-3984	clearance	abstract[198]|abstract[200]	giv[198]|new[200]	_	_
30-13	3985-3987	of	abstract[198]|abstract[200]	giv[198]|new[200]	_	_
30-14	3988-3993	liver	abstract[198]|abstract[200]|object|substance[202]	giv[198]|new[200]|giv|giv[202]	coref|coref	35-19[229_0]|39-14[254_202]
30-15	3994-3997	fat	abstract[198]|abstract[200]|substance[202]	giv[198]|new[200]|giv[202]	_	_
30-16	3998-3999	:	_	_	_	_
30-17	4000-4007	fasting	event	giv	coref	33-4
30-18	4008-4021	significantly	_	_	_	_
30-19	4022-4029	reduced	_	_	_	_
30-20	4030-4033	FLI	abstract	giv	coref	30-30
30-21	4034-4037	and	_	_	_	_
30-22	4038-4047	increased	abstract	new	coref	35-11[225_0]
30-23	4048-4051	the	abstract[205]	new[205]	_	_
30-24	4052-4062	proportion	abstract[205]	new[205]	_	_
30-25	4063-4065	of	abstract[205]	new[205]	_	_
30-26	4066-4074	patients	abstract[205]|person[206]	new[205]|giv[206]	coref	40-1[255_206]
30-27	4075-4082	without	abstract[205]|person[206]	new[205]|giv[206]	_	_
30-28	4083-4088	NAFLD	abstract[205]|person[206]|abstract	new[205]|giv[206]|giv	coref	37-15
30-29	4089-4090	(	_	_	_	_
30-30	4091-4094	FLI	abstract	giv	coref	33-14[217_0]
30-31	4095-4096	<	_	_	_	_
30-32	4097-4099	30	organization[209]	new[209]	_	_
30-33	4100-4105	units	organization[209]	new[209]	_	_
30-34	4106-4107	;	_	_	_	_

#Text=Figure 2
31-1	4108-4114	Figure	abstract[210]	new[210]	_	_
31-2	4115-4116	2	abstract[210]	new[210]	_	_

#Text=) .
32-1	4117-4118	)	_	_	_	_
32-2	4119-4120	.	_	_	_	_

#Text=The effects of fasting therapy were stronger in males and in individuals with higher baseline FLI , higher GOT , and higher cholesterol levels .
33-1	4121-4124	The	abstract[211]	new[211]	_	_
33-2	4125-4132	effects	abstract[211]	new[211]	_	_
33-3	4133-4135	of	abstract[211]	new[211]	_	_
33-4	4136-4143	fasting	abstract[211]|event|abstract[213]	new[211]|giv|giv[213]	coref	34-3
33-5	4144-4151	therapy	abstract[211]|abstract[213]	new[211]|giv[213]	_	_
33-6	4152-4156	were	_	_	_	_
33-7	4157-4165	stronger	_	_	_	_
33-8	4166-4168	in	_	_	_	_
33-9	4169-4174	males	person	new	_	_
33-10	4175-4178	and	_	_	_	_
33-11	4179-4181	in	_	_	_	_
33-12	4182-4193	individuals	person[215]	new[215]	_	_
33-13	4194-4198	with	person[215]	new[215]	_	_
33-14	4199-4205	higher	person[215]|abstract[217]	new[215]|giv[217]	coref	34-7[222_217]
33-15	4206-4214	baseline	person[215]|abstract|abstract[217]	new[215]|new|giv[217]	_	_
33-16	4215-4218	FLI	person[215]|abstract[217]	new[215]|giv[217]	_	_
33-17	4219-4220	,	person[215]	new[215]	_	_
33-18	4221-4227	higher	person[215]|abstract[218]	new[215]|new[218]	coref	43-19[0_218]
33-19	4228-4231	GOT	person[215]|abstract[218]	new[215]|new[218]	_	_
33-20	4232-4233	,	person[215]	new[215]	_	_
33-21	4234-4237	and	person[215]	new[215]	_	_
33-22	4238-4244	higher	person[215]|abstract[219]	new[215]|giv[219]	coref	42-8[282_219]
33-23	4245-4256	cholesterol	person[215]|abstract[219]	new[215]|giv[219]	_	_
33-24	4257-4263	levels	person[215]|abstract[219]	new[215]|giv[219]	_	_
33-25	4264-4265	.	_	_	_	_

#Text=Each additional fasting day further decreased the FLI .
34-1	4266-4270	Each	time[221]	new[221]	_	_
34-2	4271-4281	additional	time[221]	new[221]	_	_
34-3	4282-4289	fasting	event|time[221]	giv|new[221]	coref	35-10
34-4	4290-4293	day	time[221]	new[221]	_	_
34-5	4294-4301	further	_	_	_	_
34-6	4302-4311	decreased	_	_	_	_
34-7	4312-4315	the	abstract[222]	giv[222]	coref	35-24[230_222]
34-8	4316-4319	FLI	abstract[222]	giv[222]	_	_
34-9	4320-4321	.	_	_	_	_

#Text=The binary logistic regression showed that every day of fasting increase by 40 % the chance to improve a manifest fatty liver ( FLI > 60 ) and switch to a lower category of risk .
35-1	4322-4325	The	abstract[223]	new[223]	_	_
35-2	4326-4332	binary	abstract[223]	new[223]	_	_
35-3	4333-4341	logistic	abstract[223]	new[223]	_	_
35-4	4342-4352	regression	abstract[223]	new[223]	_	_
35-5	4353-4359	showed	_	_	_	_
35-6	4360-4364	that	_	_	_	_
35-7	4365-4370	every	_	_	_	_
35-8	4371-4374	day	_	_	_	_
35-9	4375-4377	of	_	_	_	_
35-10	4378-4385	fasting	event	giv	coref	36-7
35-11	4386-4394	increase	abstract[225]	new[225]	_	_
35-12	4395-4397	by	abstract[225]	new[225]	_	_
35-13	4398-4400	40	abstract[225]|abstract[226]	new[225]|new[226]	_	_
35-14	4401-4402	%	abstract[225]|abstract[226]	new[225]|new[226]	_	_
35-15	4403-4406	the	abstract[225]|abstract[227]	new[225]|new[227]	_	_
35-16	4407-4413	chance	abstract[225]|abstract[227]	new[225]|new[227]	_	_
35-17	4414-4416	to	abstract[225]|abstract[227]	new[225]|new[227]	_	_
35-18	4417-4424	improve	abstract[225]|abstract[227]|abstract	new[225]|new[227]|new	coref	40-39[268_0]
35-19	4425-4426	a	abstract[225]|abstract[227]|object[229]	new[225]|new[227]|giv[229]	coref	36-13[236_229]
35-20	4427-4435	manifest	abstract[225]|abstract[227]|object[229]	new[225]|new[227]|giv[229]	_	_
35-21	4436-4441	fatty	abstract[225]|abstract[227]|abstract|object[229]	new[225]|new[227]|giv|giv[229]	_	_
35-22	4442-4447	liver	abstract[225]|abstract[227]|object[229]	new[225]|new[227]|giv[229]	_	_
35-23	4448-4449	(	abstract[225]|abstract[227]	new[225]|new[227]	_	_
35-24	4450-4453	FLI	abstract[225]|abstract[227]|abstract[230]	new[225]|new[227]|giv[230]	coref	40-8[0_230]
35-25	4454-4455	>	abstract[225]|abstract[227]|abstract[230]	new[225]|new[227]|giv[230]	_	_
35-26	4456-4458	60	abstract[225]|abstract[227]|abstract[230]	new[225]|new[227]|giv[230]	_	_
35-27	4459-4460	)	abstract[225]|abstract[227]	new[225]|new[227]	_	_
35-28	4461-4464	and	abstract[225]|abstract[227]	new[225]|new[227]	_	_
35-29	4465-4471	switch	abstract[225]|abstract[227]	new[225]|new[227]	_	_
35-30	4472-4474	to	_	_	_	_
35-31	4475-4476	a	abstract[231]	new[231]	_	_
35-32	4477-4482	lower	abstract[231]	new[231]	_	_
35-33	4483-4491	category	abstract[231]	new[231]	_	_
35-34	4492-4494	of	abstract[231]	new[231]	_	_
35-35	4495-4499	risk	abstract[231]|abstract	new[231]|new	ana	36-1
35-36	4500-4501	.	_	_	_	_

#Text=This implies that the duration of fasting must be sufficient to influence fatty liver positively .
36-1	4502-4506	This	abstract	giv	_	_
36-2	4507-4514	implies	_	_	_	_
36-3	4515-4519	that	_	_	_	_
36-4	4520-4523	the	time[234]	new[234]	_	_
36-5	4524-4532	duration	time[234]	new[234]	_	_
36-6	4533-4535	of	time[234]	new[234]	_	_
36-7	4536-4543	fasting	time[234]|event	new[234]|giv	ana	37-1
36-8	4544-4548	must	_	_	_	_
36-9	4549-4551	be	_	_	_	_
36-10	4552-4562	sufficient	_	_	_	_
36-11	4563-4565	to	_	_	_	_
36-12	4566-4575	influence	_	_	_	_
36-13	4576-4581	fatty	object[236]	giv[236]	coref	39-14[0_236]
36-14	4582-4587	liver	object[236]	giv[236]	_	_
36-15	4588-4598	positively	_	_	_	_
36-16	4599-4600	.	_	_	_	_

#Text=This should be taken into account when periodic fasting is considered as treatment for NAFLD .
37-1	4601-4605	This	event	giv	coref	37-8[238_0]
37-2	4606-4612	should	_	_	_	_
37-3	4613-4615	be	_	_	_	_
37-4	4616-4621	taken	_	_	_	_
37-5	4622-4626	into	_	_	_	_
37-6	4627-4634	account	_	_	_	_
37-7	4635-4639	when	_	_	_	_
37-8	4640-4648	periodic	event[238]	giv[238]	coref	40-21[0_238]
37-9	4649-4656	fasting	event[238]	giv[238]	_	_
37-10	4657-4659	is	_	_	_	_
37-11	4660-4670	considered	_	_	_	_
37-12	4671-4673	as	_	_	_	_
37-13	4674-4683	treatment	abstract[239]	new[239]	_	_
37-14	4684-4687	for	abstract[239]	new[239]	_	_
37-15	4688-4693	NAFLD	abstract[239]|abstract	new[239]|giv	coref	38-14
37-16	4694-4695	.	_	_	_	_

#Text=As already mentioned , insulin resistance , T2DM , and the development of NAFLD are closely associated conditions .
38-1	4696-4698	As	_	_	_	_
38-2	4699-4706	already	abstract[247]	giv[247]	coref	38-2[247_243]
38-3	4707-4716	mentioned	abstract[247]	giv[247]	_	_
38-4	4717-4718	,	abstract[247]	giv[247]	_	_
38-5	4719-4726	insulin	substance|abstract[242]|abstract[243]|abstract[247]	giv|giv[242]|new[243]|giv[247]	coref|coref	42-4|42-4[281_242]
38-6	4727-4737	resistance	abstract[242]|abstract[243]|abstract[247]	giv[242]|new[243]|giv[247]	_	_
38-7	4738-4739	,	abstract[243]|abstract[247]	new[243]|giv[247]	_	_
38-8	4740-4744	T2DM	abstract[243]|abstract|abstract[247]	new[243]|giv|giv[247]	coref	39-9
38-9	4745-4746	,	abstract[243]|abstract[247]	new[243]|giv[247]	_	_
38-10	4747-4750	and	abstract[243]|abstract[247]	new[243]|giv[247]	_	_
38-11	4751-4754	the	abstract[243]|event[245]|abstract[247]	new[243]|new[245]|giv[247]	_	_
38-12	4755-4766	development	abstract[243]|event[245]|abstract[247]	new[243]|new[245]|giv[247]	_	_
38-13	4767-4769	of	abstract[243]|event[245]|abstract[247]	new[243]|new[245]|giv[247]	_	_
38-14	4770-4775	NAFLD	abstract[243]|event[245]|abstract|abstract[247]	new[243]|new[245]|giv|giv[247]	coref	42-13
38-15	4776-4779	are	abstract[247]	giv[247]	_	_
38-16	4780-4787	closely	abstract[247]	giv[247]	_	_
38-17	4788-4798	associated	abstract[247]	giv[247]	_	_
38-18	4799-4809	conditions	abstract[247]	giv[247]	_	_
38-19	4810-4811	.	_	_	_	_

#Text=Taylor et al. have shown that remission of T2DM requires a decrease of liver fat .
39-1	4812-4818	Taylor	person	new	_	_
39-2	4819-4821	et	_	_	_	_
39-3	4822-4825	al.	person	new	_	_
39-4	4826-4830	have	_	_	_	_
39-5	4831-4836	shown	_	_	_	_
39-6	4837-4841	that	_	_	_	_
39-7	4842-4851	remission	event[250]	new[250]	_	_
39-8	4852-4854	of	event[250]	new[250]	_	_
39-9	4855-4859	T2DM	event[250]|abstract	new[250]|giv	_	_
39-10	4860-4868	requires	_	_	_	_
39-11	4869-4870	a	event[252]	new[252]	_	_
39-12	4871-4879	decrease	event[252]	new[252]	_	_
39-13	4880-4882	of	event[252]	new[252]	_	_
39-14	4883-4888	liver	event[252]|object|substance[254]	new[252]|giv|giv[254]	coref	42-1
39-15	4889-4892	fat	event[252]|substance[254]	new[252]|giv[254]	_	_
39-16	4893-4894	.	_	_	_	_

#Text=Patients with T2DM tend to have higher FLI scores , but in this study , we could demonstrate that the fasting intervention was equally effective in T2DM patients and in non-diabetic subjects in terms of FLI , although the improvement of other parameters ( e.g. , HDL , LDL , and AP ) was not as complete .
40-1	4895-4903	Patients	person[255]	giv[255]	coref	40-27[264_255]
40-2	4904-4908	with	person[255]	giv[255]	_	_
40-3	4909-4913	T2DM	person[255]|abstract	giv[255]|giv	coref	40-27
40-4	4914-4918	tend	_	_	_	_
40-5	4919-4921	to	_	_	_	_
40-6	4922-4926	have	_	_	_	_
40-7	4927-4933	higher	abstract[258]	new[258]	_	_
40-8	4934-4937	FLI	abstract|abstract[258]	giv|new[258]	coref	40-36
40-9	4938-4944	scores	abstract[258]	new[258]	_	_
40-10	4945-4946	,	_	_	_	_
40-11	4947-4950	but	_	_	_	_
40-12	4951-4953	in	_	_	_	_
40-13	4954-4958	this	abstract[259]	new[259]	coref	41-7[275_259]
40-14	4959-4964	study	abstract[259]	new[259]	_	_
40-15	4965-4966	,	_	_	_	_
40-16	4967-4969	we	person	giv	ana	43-1
40-17	4970-4975	could	_	_	_	_
40-18	4976-4987	demonstrate	_	_	_	_
40-19	4988-4992	that	_	_	_	_
40-20	4993-4996	the	event[262]	new[262]	coref	43-28[297_262]
40-21	4997-5004	fasting	event|event[262]	giv|new[262]	coref	41-11[276_0]
40-22	5005-5017	intervention	event[262]	new[262]	_	_
40-23	5018-5021	was	_	_	_	_
40-24	5022-5029	equally	_	_	_	_
40-25	5030-5039	effective	_	_	_	_
40-26	5040-5042	in	_	_	_	_
40-27	5043-5047	T2DM	abstract|person[264]|person[265]	giv|giv[264]|giv[265]	coref|coref	40-27[265_264]|41-14
40-28	5048-5056	patients	person[264]|person[265]	giv[264]|giv[265]	_	_
40-29	5057-5060	and	person[265]	giv[265]	_	_
40-30	5061-5063	in	person[265]	giv[265]	_	_
40-31	5064-5076	non-diabetic	person[265]|animal[266]	giv[265]|new[266]	coref	43-36[299_266]
40-32	5077-5085	subjects	person[265]|animal[266]	giv[265]|new[266]	_	_
40-33	5086-5088	in	_	_	_	_
40-34	5089-5094	terms	_	_	_	_
40-35	5095-5097	of	_	_	_	_
40-36	5098-5101	FLI	abstract	giv	coref	43-9
40-37	5102-5103	,	_	_	_	_
40-38	5104-5112	although	_	_	_	_
40-39	5113-5116	the	abstract[268]	new[268]	_	_
40-40	5117-5128	improvement	abstract[268]	new[268]	_	_
40-41	5129-5131	of	abstract[268]	new[268]	_	_
40-42	5132-5137	other	abstract[268]|abstract[269]	new[268]|new[269]	appos	40-45[270_269]
40-43	5138-5148	parameters	abstract[268]|abstract[269]	new[268]|new[269]	_	_
40-44	5149-5150	(	_	_	_	_
40-45	5151-5155	e.g.	abstract[270]|abstract[271]	giv[270]|giv[271]	appos|appos	40-45[271_270]|40-49[0_271]
40-46	5156-5157	,	abstract[270]|abstract[271]	giv[270]|giv[271]	_	_
40-47	5158-5161	HDL	abstract[270]|abstract[271]	giv[270]|giv[271]	_	_
40-48	5162-5163	,	abstract[270]|abstract[271]	giv[270]|giv[271]	_	_
40-49	5164-5167	LDL	abstract[270]|abstract[271]|abstract	giv[270]|giv[271]|giv	coref	43-22[295_0]
40-50	5168-5169	,	abstract[270]|abstract[271]	giv[270]|giv[271]	_	_
40-51	5170-5173	and	abstract[270]|abstract[271]	giv[270]|giv[271]	_	_
40-52	5174-5176	AP	abstract[270]|abstract[271]|abstract	giv[270]|giv[271]|new	_	_
40-53	5177-5178	)	_	_	_	_
40-54	5179-5182	was	_	_	_	_
40-55	5183-5186	not	_	_	_	_
40-56	5187-5189	as	_	_	_	_
40-57	5190-5198	complete	_	_	_	_
40-58	5199-5200	.	_	_	_	_

#Text=These results are in line with a previous study on periodic fasting in T2DM .
41-1	5201-5206	These	abstract[274]	new[274]	coref	43-1[285_274]
41-2	5207-5214	results	abstract[274]	new[274]	_	_
41-3	5215-5218	are	_	_	_	_
41-4	5219-5221	in	_	_	_	_
41-5	5222-5226	line	_	_	_	_
41-6	5227-5231	with	_	_	_	_
41-7	5232-5233	a	abstract[275]	giv[275]	_	_
41-8	5234-5242	previous	abstract[275]	giv[275]	_	_
41-9	5243-5248	study	abstract[275]	giv[275]	_	_
41-10	5249-5251	on	abstract[275]	giv[275]	_	_
41-11	5252-5260	periodic	abstract[275]|event[276]	giv[275]|giv[276]	_	_
41-12	5261-5268	fasting	abstract[275]|event[276]	giv[275]|giv[276]	_	_
41-13	5269-5271	in	abstract[275]|event[276]	giv[275]|giv[276]	_	_
41-14	5272-5276	T2DM	abstract[275]|event[276]|abstract	giv[275]|giv[276]|giv	coref	43-38
41-15	5277-5278	.	_	_	_	_

#Text=Liver enzymes , insulin resistance , and cholesterol levels are related in NAFLD .
42-1	5279-5284	Liver	object|abstract[279]	giv|new[279]	coref|coref	43-13|43-13[291_279]
42-2	5285-5292	enzymes	abstract[279]	new[279]	_	_
42-3	5293-5294	,	_	_	_	_
42-4	5295-5302	insulin	substance|abstract[281]	giv|giv[281]	_	_
42-5	5303-5313	resistance	abstract[281]	giv[281]	_	_
42-6	5314-5315	,	_	_	_	_
42-7	5316-5319	and	_	_	_	_
42-8	5320-5331	cholesterol	abstract[282]	giv[282]	_	_
42-9	5332-5338	levels	abstract[282]	giv[282]	_	_
42-10	5339-5342	are	_	_	_	_
42-11	5343-5350	related	_	_	_	_
42-12	5351-5353	in	_	_	_	_
42-13	5354-5359	NAFLD	abstract	giv	_	_
42-14	5360-5361	.	_	_	_	_

#Text=Our results supported a correlation between changes in FLI and changes in liver enzymes ( GGT , and GOT ) and lipid parameters ( TG ) after fasting intervention , although this was limited to subjects without T2DM .
43-1	5362-5365	Our	person|abstract[285]	giv|giv[285]	_	_
43-2	5366-5373	results	abstract[285]	giv[285]	_	_
43-3	5374-5383	supported	_	_	_	_
43-4	5384-5385	a	abstract[286]	new[286]	_	_
43-5	5386-5397	correlation	abstract[286]	new[286]	_	_
43-6	5398-5405	between	abstract[286]	new[286]	_	_
43-7	5406-5413	changes	abstract[286]|abstract[287]	new[286]|new[287]	_	_
43-8	5414-5416	in	abstract[286]|abstract[287]	new[286]|new[287]	_	_
43-9	5417-5420	FLI	abstract[286]|abstract[287]|abstract	new[286]|new[287]|giv	_	_
43-10	5421-5424	and	abstract[286]	new[286]	_	_
43-11	5425-5432	changes	abstract[286]|abstract[289]	new[286]|new[289]	_	_
43-12	5433-5435	in	abstract[286]|abstract[289]	new[286]|new[289]	_	_
43-13	5436-5441	liver	abstract[286]|abstract[289]|object|abstract[291]	new[286]|new[289]|giv|giv[291]	_	_
43-14	5442-5449	enzymes	abstract[286]|abstract[289]|abstract[291]	new[286]|new[289]|giv[291]	_	_
43-15	5450-5451	(	abstract[286]	new[286]	_	_
43-16	5452-5455	GGT	abstract[286]|abstract	new[286]|new	_	_
43-17	5456-5457	,	abstract[286]	new[286]	_	_
43-18	5458-5461	and	abstract[286]	new[286]	_	_
43-19	5462-5465	GOT	abstract[286]|abstract	new[286]|giv	_	_
43-20	5466-5467	)	abstract[286]	new[286]	_	_
43-21	5468-5471	and	abstract[286]	new[286]	_	_
43-22	5472-5477	lipid	abstract[286]|substance|abstract[295]	new[286]|giv|giv[295]	appos	43-25[0_295]
43-23	5478-5488	parameters	abstract[286]|abstract[295]	new[286]|giv[295]	_	_
43-24	5489-5490	(	_	_	_	_
43-25	5491-5493	TG	abstract	giv	_	_
43-26	5494-5495	)	_	_	_	_
43-27	5496-5501	after	_	_	_	_
43-28	5502-5509	fasting	event[297]	giv[297]	ana	43-32[0_297]
43-29	5510-5522	intervention	event[297]	giv[297]	_	_
43-30	5523-5524	,	_	_	_	_
43-31	5525-5533	although	_	_	_	_
43-32	5534-5538	this	event	giv	_	_
43-33	5539-5542	was	_	_	_	_
43-34	5543-5550	limited	_	_	_	_
43-35	5551-5553	to	_	_	_	_
43-36	5554-5562	subjects	animal[299]	giv[299]	_	_
43-37	5563-5570	without	animal[299]	giv[299]	_	_
43-38	5571-5575	T2DM	animal[299]|abstract	giv[299]|giv	_	_
43-39	5576-5577	.	_	_	_	_
